Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.
about
Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and InhibinMusculoskeletal complications of haematological diseaseActivin A inhibits RANKL-mediated osteoclast formation, movement and function in murine bone marrow macrophage cultures.Bone anabolics in osteoporosis: Actuality and perspectivesSmad-dependent mechanisms of inflammatory bone destructionSilencing the expression of connexin 43 decreases inflammation and joint destruction in experimental arthritisRas dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model.Treatment of multiple myeloma bone disease: experimental and clinical data.Novel therapeutic targets in myeloma bone disease.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeuticsMyostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice.THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritisSotatercept in patients with osteolytic lesions of multiple myeloma.Modulation of amniotic fluid activin-a and inhibin-a in women with preterm premature rupture of the membranes and infection-induced preterm birth.Cancer-targeted therapies and radiopharmaceuticalsUpdate on bone anabolics in osteoporosis treatment: rationale, current status, and perspectivesDetection of differentially expressed glycogenes in trabecular meshwork of eyes with primary open-angle glaucoma.Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia.Utilizing BMP-2 muteins for treatment of multiple myelomaEffects of myokines on bone.Activin signaling as an emerging target for therapeutic interventionsEffects of proteasome inhibitors on bone cancerWhen versatility matters: activins/inhibins as key regulators of immunity.Prevention and treatment of myeloma bone disease.Management of bone disease in multiple myeloma.Transcriptional profiling of in vitro smooth muscle cell differentiation identifies specific patterns of gene and pathway activation.Emerging treatment approaches for myeloma-related bone disease.Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma.Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors.miR-217 Is a Useful Diagnostic Biomarker and Regulates Human Podocyte Cells Apoptosis via Targeting TNFSF11 in Membranous Nephropathy.Pathogenesis of bone disease in multiple myeloma: from bench to bedside.Mechanisms of bone destruction in multiple myeloma.Activin A inhibition attenuates sympathetic neural remodeling following myocardial infarction in rats.Anabolic Strategies to Augment Bone Fracture Healing.Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder
P2860
Q24633744-9BF648D3-D7F9-4B8D-B4CB-B82E6EF9FF9EQ26786755-66EAC64A-3F5C-406E-9617-65DDF6F84611Q27342550-20DAA1CF-EE22-473D-B420-D013AE41DE30Q27691122-2F55B630-EE9B-41DE-9253-0777FF585FEFQ28066288-A65BC42D-44E5-4DF1-A104-2388F862BD90Q28575897-52620165-075A-444E-B9A6-1F453CFB881FQ30375214-2D49B26E-F98B-44F5-85F8-33EC83D9866EQ30868833-7A2C93F9-2D8A-449A-BF53-4FDCF09F8926Q34025065-5CA61EF3-EAC9-4470-AEBE-BE8BE39881E5Q34038854-48F4D72A-5BA6-4E0B-BEC1-E12005E65FB6Q34488033-9117455A-E945-405F-AE54-C8FEC1C4B804Q34895962-E5BCF5B8-C31D-4E0B-88CD-BAA6694D2AC2Q35035011-66336D83-A14B-416D-B1E6-5CA27BA97A92Q35659094-F3A9C0B0-676D-431A-BDD6-B81132CB5E8FQ35683440-961D488D-0169-497E-8D0E-AF7F296440ABQ35744492-2FC21772-2B33-4AF7-9037-34325F49C48DQ35925346-14E57EA8-67DE-4E0E-A87A-370F9648A101Q36092598-C6191F58-998C-4F34-A5CE-5310ADE43FCBQ36367921-32D2703A-B6FC-4D19-90E4-73096A11C792Q37112054-643BDBE2-EBDC-4E29-9CBD-7768E97A5869Q37268461-3D5D4B09-AFE3-4E8D-81F3-8F348ADFA425Q37281071-2B0D27D7-8051-484C-B9EB-BFD7C5EA9BB6Q37871336-DB29BA45-C3C4-4BC3-9E8E-3EC2B6998532Q38039879-8AC6A07A-5AC5-4B3B-BBF3-A08895883863Q38179039-BF870097-84BE-4033-A3F9-D6870FCBA567Q38521662-27874FE3-7199-408B-99B5-CEEF38BF2994Q39090721-CFFF10C5-467D-4EA2-99EA-DA14C3E01735Q40330082-27F3FCFE-DA3B-4352-B4F2-047215329D12Q41146384-2ECF9B2F-100F-4BAD-9D11-EF1C5E463F54Q45151645-019B98D3-66AF-437B-908D-C9B6DCD1054DQ47109928-D03341B9-ABBF-4507-94AD-45B894C54581Q47734632-F0B89756-A7DE-4071-8EFB-DA6BAB0E532FQ47756922-D69D20DA-B3A9-46E6-BE9D-A8E3BF2ACD70Q49379171-1BF74C9F-AAE4-4977-84A6-D55D1795ECC0Q55411806-B41D3A19-950F-442B-8C0D-3485FABE5BBCQ58710472-92C8C80E-3F38-47A6-9C10-8E914A098712
P2860
Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Activin A stimulates IkappaB-a ...... hway in osteoclast precursors.
@en
Activin A stimulates IkappaB-a ...... hway in osteoclast precursors.
@nl
type
label
Activin A stimulates IkappaB-a ...... hway in osteoclast precursors.
@en
Activin A stimulates IkappaB-a ...... hway in osteoclast precursors.
@nl
prefLabel
Activin A stimulates IkappaB-a ...... hway in osteoclast precursors.
@en
Activin A stimulates IkappaB-a ...... hway in osteoclast precursors.
@nl
P2093
P356
P1476
Activin A stimulates IkappaB-a ...... hway in osteoclast precursors.
@en
P2093
K A Hruska
T Sugatani
U M Alvarez
P356
10.1002/JCB.10613
P577
2003-09-01T00:00:00Z